Cory Funk
Senior Research Scientist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2025
Background Alzheimer’s disease (AD) leading to cognitive decline and dementia results from the interplay of multiple interacting dysfunctional biological systems. These systems can be categorized by domain , such as inflammation, cardiovascular health, proteostasis, or metabolism. Specific causes of AD differ between individuals, but each individual is likely to have causes stemming from multiple domains. Personalized multidomain therapy has been proposed as a standard of care for AD. Objectives We sought to enumerate and describe prospective randomized controlled trials (RCTs) for multidomain interventions for AD, and to extract their inclusion criteria, trial design parameters (length, number of participants), and outcome measures. We sought to clarify gaps and opportunities in research and clinical translation. Eligibility criteria We include all cohort studies and RCTs for multidomain (also known as multimodal, multicomponent, multidimensional, or multisystem) therapy of any stage of AD. Results There have been 22 studies (completed or reported as ongoing) of multidomain interventions for AD, including 18 RCTs. Of the 14 completed RCTs, 11 demonstrate benefit from their intervention in at least one arm. Conclusions Although these RCTs differ widely in their parameters, the majority support the use of multidomain therapy, and show effect sizes greater than reported for unimodal therapies, including pharmaceuticals. Multidomain therapy should be the standard of care for AD. Multidomain interventions (also known as treatments) should be employed widely, early, and first-line. Treatment or prevention is likely to be most effective at early, presymptomatic stages, but is worthwhile at all stages of disease. In order to influence multiple domains, multiple modes of therapy are likely necessary in all patients. Some individual modes, such as particular lifestyle interventions, may target multiple domains. Nevertheless, most patients will benefit from multiple modes of intervention (multimodal intervention) that together target multiple domains. Standard-of-care guidelines should explicitly include multidomain interventions. Future clinical trials must be designed to iteratively improve multidomain therapies. Payors should embrace reimbursement for effective multidomain intervention, including personalized coaching.
Year:
2025
The emergence of single nucleus RNA sequencing (snRNA-seq) offers to revolutionize the study of Alzheimer’s disease (AD). Integration with complementary multiomics data such as genetics, proteomics and clinical data provides powerful opportunities to link cell subpopulations and molecular networks with a broader disease-relevant context. We report snRNA-seq profiles from superior frontal gyrus samples from 101 well characterized subjects from the Banner Brain and Body Donation Program in combination with whole genome sequences. We report findings that link common AD risk variants with CR1 expression in oligodendrocytes as well as alterations in hematological parameters. We observed an AD-associated CD83(+) microglial subtype with unique molecular networks and which is associated with immunoglobulin IgG4 production in the transverse colon. Our major observations were replicated in two additional, independent snRNA-seq data sets. These findings illustrate the power of multi-tissue molecular profiling to contextualize snRNA-seq brain transcriptomics and reveal disease biology.
Year:
2024
Apolipoprotein E ( APOE ) modifies human aging; specifically, the ε2 and ε4 alleles are among the strongest genetic predictors of longevity and Alzheimer’s disease (AD) risk, respectively. However, detailed mechanisms for their influence on aging remain unclear. Herein, we analyzed inter-omic, context-dependent association patterns across APOE genotypes, sex, and health axes in 2,229 community-dwelling individuals to test APOE genotypes for variation in metabolites and metabolite-associations tied to a previously-validated metric of biological aging (BA) based on blood biomarkers. Our analysis, supported by validation in an independent cohort, identified top APOE -associated plasma metabolites as diacylglycerols, which were increased in ε2-carriers and trended higher in ε4-carriers compared to ε3-homozygotes, despite the known opposing aging effects of the allele variants. ‘Omics association patterns of ε2-carriers and increased biological age were also counter-intuitively similar, displaying increased associations between insulin resistance markers and energy-generating pathway metabolites. These results provide an atlas of APOE -related ‘omic associations and support the involvement of bioenergetic pathways in mediating the impact of APOE on aging.
Year:
2024
Age and APOE genotype are the strongest known risk factors for late-onset Alzheimer’s disease (AD), but the mechanisms linking them to neuronal loss remain incompletely defined. Using multiomic data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), we propose a unified hypothesis in which two interdependent failure modes—saturation of microglial lipid flux capacity and disruption of the astrocyte–neuron lactate shuttle (ANLS) due to excess astrocytic membrane cholesterol—drive disease progression upstream of amyloid and tau pathology. Stratifying participants by cognitive score quartiles, we find consistent associations linking impaired lipid clearance, metabolic stress, and genetic variants regulating cholesterol handling. These processes appear to reinforce each other, resulting in accelerating neurodegeneration. Our hypothesis reframes AD as a systems-level collapse in metabolic coordination, rather than a purely linear pathological cascade. These insights emerged during the development of digital twin models for personalized interventions, highlighting the power of systems approaches to reveal hidden drivers of neurodegeneration.
Year:
2024
The identification of microglia subtypes is important for understanding the role of innate immunity in neu-rodegenerative diseases. Current methods of unsupervised cell type identification assume a small noise-to-signal ratio of transcriptome measurements that would produce well-separated cell clusters. However, identification of subtypes is obscured by gene expression noise, diminishing the distances in transcriptome space between distinct cell types and blurring boundaries. Here we use Fokker-Planck (FP) diffusion maps to model cellular differentiation as a stochastic process whereby cells settle into local minima, corresponding to cell subtypes, in a potential landscape constructed from transcriptome data using a nearest neighbor graph approach. By applying critical transition fields, we identify individual cells on the verge of transitioning between subtypes, revealing microglial cells in inactivated, homeostatic state before radially transitioning into various specialized subtypes. Specifically, we show that cells from Alzheimer’s disease patients are enriched in a microglia subtype associated to antigen presentation and T-cell recruitment.
Year:
2024
Mitochondrial dysfunction is well documented in Alzheimer’s Disease (AD). However, whether it instigates the onset of AD remains unclear. We demonstrate that a reduction of complex I activity in wild type (WT) mice caused by a global knockout of Ndufs4 , an accessory mitochondrial complex I subunit, was sufficient to induce transcriptomic changes in the brain reminiscent of those observed in AD patients and familial mouse models of AD. Reduced complex I activity affected expression of genes in the networks related to mitochondrial homeostasis, neuronal and synaptic function. Transcriptomic signatures in male and female Ndufs4 -/- mice reflected a different severity of AD phenotype. Unexpectedly, these changes were partially rescued by a neuroprotective small molecule mild complex I inhibitor CP2. Consistent with studies in AD mice, CP2 treatment in Ndufs4 -/- mice augmented the expression of genes associated with mitochondrial biogenesis and turnover, synaptic activity, autophagy, redox balance, and reduced expression of genes related to inflammation. Female Ndufs4 -/- mice demonstrated a greater reversal of gene expression toward WT mice. These studies provide further support for mitochondria as a causative factor of AD pathophysiology and complex I as a putative therapeutic target.
Year:
2024
Collaborators (20)
Sean Gibbons
Professor
University of Washington
Gwênlyn Glusman
Principal Scientist
Institute for Systems Biology
Todd Golde
Professor and Center Director
Emory University
David Merrill
Associate Professor
John Wayne Cancer Institute
Mark Mapstone
Professor
University of California Irvine School of Medicine
Michael S. Lustgarten
Tufts University
Eugenia Trushina
Professor
Mayo Clinic Minnesota
Nathan Price
Professor and Co-Director, Center for Human Healthspan
Buck Institute for Research on Aging
Jennifer Bramen
Director, Neuroimaging
-
Timothy Hohman
Professor
Vanderbilt University Medical Center
Ryan Glatt
-
Jennifer Hadlock
Associate Professor, Director of Medical Data Science
Institute for Systems Biology
Diego Mastroeni
Associate Proffessor
Arizona State University
Oliver Fiehn
Professor
University of California, Davis
Jaroslav Bendl
Assistant Professor
Icahn School of Medicine at Mount Sinai
Priyanka Baloni
Assistant Professor
Purdue University
Allan I. Levey
Emory University School of Medicine
Kengo Watanabe
Division Head
Tokushima University
Jared C Roach
Senior Research Scientist
Institute for Systems Biology
Cyrus Raji
Associate Professor of Radiology and Neurology
Washington University in St. Louis
Make your next move.
Prepare your application
Review drafts before you send them.